Hangzhou Biosunpharma’s OB756 New Drug Application Accepted for Myelofibrosis Treatment by China’s NMPA
Hangzhou Biosunpharma Co., Ltd. has announced that the National Medical Products Administration (NMPA) has accepted...
R&D Investments and Operating Cash Flows Highlight Resilience in Simcere Pharma’s H1 2024 Financial Report
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has reported its financial results for the first...
US Congressmen Call for FDA Investigation into Clinical Trials at China’s Military Hospitals
US lawmakers are intensifying their scrutiny of the involvement of Chinese military hospitals in hosting...
Jiangsu Hansoh and GSK Receive FDA Breakthrough Designation for B7-H3 Targeted ADC in Small-Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692), a prominent Chinese pharmaceutical company, and its UK...
Henlius Biotech Secures Exclusive Rights to Commercialize Convalife’s Generic Neratinib in China and Abroad
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has entered...
WuXi XDC Reports 67.6% YOY Revenue Growth and Expands Manufacturing with Singapore Plant
WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA,...
Bone Index Secures Financing to Expand Manufacturing and Promote Diagnostic Technology Globally
Bone Index, a Finland-based medical technology company specializing in bone diagnostics, has announced the successful...
Chengdu Kanghua Biological Products Reports 16.81% YOY Revenue Growth in H1 2024 Financial Results
Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841), a biopharmaceutical company based in China, has...
J&J’s Rybrevant-Lazclude Combo Approved by FDA, Challenging AstraZeneca’s Tagrisso in NSCLC Treatment
Johnson & Johnson (J&J; NYSE: JNJ) has secured a new market approval in the United...
CSPC Pharmaceutical Group Reports Moderate H1 2024 Revenue Growth with Patent Medicines Driving the Increase
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading China-based pharmaceutical enterprise, has announced its financial...
AstraZeneca’s Strensiq Approved for Rare Disease Therapy under Greater Bay Area’s Drug Access Policy
AstraZeneca (NASDAQ: AZN, LON: AZN) , a leading UK pharmaceutical company, has received approval for...
Johnson & Johnson to Acquire Israeli Cardiovascular Device Maker V-Wave for Upfront USD 600 Million
Johnson & Johnson (NYSE: JNJ), a multinational healthcare conglomerate based in the US, has announced...
China’s VBP Office Exposes Collusion Among Six Firms in Bromhexine Bidding Process
The National Drug Alliance Procurement Office, which oversees the Volume-Based Procurement (VBP) program, has issued...
US Congress Seeks FDA Action on China Military Hospital Trials and Biopharma Security
WASHINGTON—In an unprecedented move, US congressmen have intensified their demands for the US Food and...
Jiangsu Hansoh Pharmaceutical and GSK Win FDA Breakthrough Therapy Designation for B7-H3 Targeted ADC in Small-Cell Lung Cancer
LONDON/HONG KONG—Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692), in collaboration with UK-based GSK plc (NYSE:...
Shanghai Henlius Biotech Secures Exclusive Rights to Convalife Pharmaceuticals’ Generic Neratinib in China
SHANGHAI—Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has entered...
WuXi XDC Accelerates Bioconjugate Drug Development with 67.6% YOY Revenue Increase in H1 2024
HONG KONG—WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi...
Finland’s Bone Index Partners with Lynx Financial for APAC and North American Market Expansion
HELSINKI—Bone Index, a pioneering medical technology company headquartered in Finland, has announced the successful completion...
Chengdu Kanghua Biological Products Soars with 16.81% YOY Revenue Growth in H1 2024 Report
CHENGDU—Chengdu Kanghua Biological Products Co., Ltd (SHE: 300841) has reported a significant upswing in its...
Johnson & Johnson’s Rybrevant-Lazclude Combo Approved by FDA for First-Line NSCLC Treatment
NEW YORK—Healthcare conglomerate Johnson & Johnson (J&J; NYSE: JNJ) has secured a significant regulatory milestone...